FTC Notification Requirement For Brand/Generic Deals Begins
Executive Summary
Generic and brand drug firms entering into patent settlements must notify the Federal Trade Commission and the Department of Justice beginning Jan. 7
You may also be interested in...
FTC Sees Reduction In “Reverse” Payments From Brand To Generic Firms
"Reverse" payments from brand to generic companies in exchange for not launching a generic seem to be disappearing, the Federal Trade Commission notes
FTC Sees Reduction In “Reverse” Payments From Brand To Generic Firms
"Reverse" payments from brand to generic companies in exchange for not launching a generic seem to be disappearing, the Federal Trade Commission notes
Par Stands By “Authorized” Generics; “More Creative” Deals Coming
Drug patent dispute settlements are likely to become more "creative" in the future, Par CEO Scott Tarriff says